Bristol Myers Squibb’s Acquisition of Turning Point for $4.1 Billion has Resulted in the Successful FDA Approval of lung cancer drug Augtyro

Published: November 2023


On 16 November 2023, the Food and Drug Administration (FDA) has approved BMS's drug Augtyro (repotrectinib) developed for the treatment of non-small cell lung cancer (NSCLC) in patients with ROS1 oncogenic fusions. Augtyro's acquisition by BMS stemmed from its $4.1 billion purchase of Turning Point Therapeutics in the previous year. This recent approval presents an opportunity for BMS to compete against Pfizer's Xalkori and Roche's Rozlytrek in the treatment of ROS1-positive NSCLC, a subtype accounting for approximately 1% to 2% of all NSCLC cases.

Clinical trial data indicated that Augtyro has the potential to establish itself as a new standard-of-care option for this specific subtype of NSCLC. The trial, a single-arm phase 1/2 study, revealed that Augtyro led to tumor reduction in 79% of patients who had not previously received a tyrosine kinase inhibitor (TKI) like Augtyro, with a median response duration of 34.1 months. Additionally, among patients previously treated with one ROS1 agent but not chemotherapy, the overall response rate stood at 38%, with a median response duration of 14.8 months.

According to Roots Analysis, the Squamous Non-Small Cell Lung Cancer Market is expected to grow at a CAGR of 10.5% during the forecast period.

For detailed insights about this domain, check out our report on Squamous Non-Small Cell Lung Cancer Market or email sales@rootsanalysis.com

You may also be interested in the following titles: 

  1. Cancer Therapeutics Market, 2018-2030
  2. Cancer Biomarker Market, 2019-2030
  3. HER2-Positive Breast Cancer Market, 2021-2031

MEDIA CITATIONS

  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry